公开(公告)号：US20140031351A1

公开(公告)日：2014-01-30

申请号：US14025986

申请日：2013-09-13

Applicant: Cephalon, Inc.

Inventor： Henry J. Breslin ,  Bruce D. Dorsey ,  Gregory R. Ott

IPC: C07D487/08

CPC classification number: A61K31/529 ,  A61K31/5377 ,  C07D487/08 ,  C07D487/18

Abstract: The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.

Abstract translation: 本发明提供式I化合物或其药学上可接受的盐形式，其中R 1，R 2，R 3，R 4，R 5，A和X如本文所定义，其处理方法及其用途。

公开(公告)号：US20140024655A1

公开(公告)日：2014-01-23

申请号：US13911447

申请日：2013-06-06

Applicant: Cephalon, Inc.

Inventor： Pawel T. Dobrzanski ,  Matthew M. Seavey

IPC: A61K31/496

CPC classification number: A61K31/496

Abstract: The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject COMPOUND A

Abstract translation: 本发明提供一种用于治疗受试者的狼疮的方法，包括给予受试者化合物A的步骤

公开(公告)号：US20130338205A1

公开(公告)日：2013-12-19

申请号：US13969724

申请日：2013-08-19

Applicant: Cephalon, Inc.

Inventor： Jason Edward Brittain ,  Joe Craig Franklin

IPC: A61K31/4184

CPC classification number: A61K31/4184 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/10

Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

公开(公告)号：US08609863B2

公开(公告)日：2013-12-17

申请号：US13719379

申请日：2012-12-19

Applicant: Cephalon, Inc.

Inventor： Jason Edward Brittain ,  Joe Craig Franklin

IPC: C07D235/04

CPC classification number: A61K31/4184 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/10

Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

Abstract translation: 本发明提供了适用于药物用途的冻干苯达莫司汀的药物制剂。 本发明还提供了生产冻干的苯达莫司汀的方法。 药物制剂可用于任何对苯达莫司汀治疗敏感的疾病，如肿瘤疾病。

公开(公告)号：US20130156825A1

公开(公告)日：2013-06-20

申请号：US13773016

申请日：2013-02-21

Applicant: Cephalon, Inc.

Inventor： Moshe Bentolila ,  Aldo Shusterman ,  Moshe Arkin ,  Joseph Kaspi

IPC: A61K31/165

CPC classification number: A61K31/165 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/2077 ,  Y10T428/2982

Abstract: The invention provides an oral pharmaceutical composition comprising modafinil particles, wherein at least about 5% of said modafinil particles have a diameter greater than 200 microns.

Abstract translation: 本发明提供包含莫替非尼颗粒的口服药物组合物，其中至少约5％的所述莫达非尼颗粒具有大于200微米的直径。

公开(公告)号：US20040229940A1

公开(公告)日：2004-11-18

申请号：US10843988

申请日：2004-05-12

Applicant: Cephalon Inc

Inventor： Howard A. Hassman ,  Robert T. Hrubiec ,  Rodney J. Hughes ,  Jeffry L. Vaught

IPC: A61K031/343 ,  A61K031/165 ,  A61K031/137

CPC classification number: A61K45/06 ,  A61K31/137 ,  A61K31/165 ,  A61K31/343 ,  A61K2300/00

Abstract: Compositions and methods for the treatment of depressive disorders through the administration of modafinil with antidepressants.

公开(公告)号：US20040224008A1

公开(公告)日：2004-11-11

申请号：US10841893

申请日：2004-05-07

Applicant: Cephalon, Inc.

Inventor： Hao Zhang

IPC: A61K009/70

CPC classification number: A61K9/006 ,  A61K9/7007

Abstract: A dissolvable backing layer for use with transmucosal drug delivery devices includes a dissolvable hydrophilic region and a non-hydrophilic region that inhibits or slows migration of water, drugs, other active agents, or other molecules through the backing layer. The non-hydrophilic region can be a disperse phase of gaseous voids, droplets of a hydrophobic liquid, solid particles of a hydrophobic material, or water insoluble particles that are not necessarily hydrophobic. In the alternative, the non-hydrophilic region may comprise a continuous layer or component that is readily dispersible upon dissolving of the hydrophilic region. The backing layers may be used within any transmucosal delivery device used to delivery drugs or other active agents across a mucosal surface.

Abstract translation: 用于经粘膜药物递送装置的可溶解背衬层包括可溶性亲水区域和非亲水区域，其通过背衬层抑制或减缓水，药物，其它活性剂或其它分子的迁移。 非亲水区域可以是气态空隙的分散相，疏水液体的液滴，疏水性材料的固体颗粒或不一定是疏水性的水不溶性颗粒。 在替代方案中，非亲水区域可以包括在亲水区域溶解时容易分散的连续层或组分。 背衬层可以用于穿过粘膜表面递送药物或其它活性剂的任何经粘膜递送装置。

公开(公告)号：US20040186157A1

公开(公告)日：2004-09-23

申请号：US10755505

申请日：2004-01-12

Applicant: Cephalon, Inc.

Inventor： Robert L. Hudkins ,  Dandu R. Reddy ,  Jasbir Singh ,  Rabindranath Tripathy ,  Ted Underiner

IPC: A61K031/407 ,  C07D209/56

CPC classification number: C07D487/04 ,  C07D209/94

Abstract: The present invention is directed to cyclic substituted fused pyrrolocarbazoles and isoindolones. The invention also is directed to methods for making and using the cyclic substituted fused pyrrolocarbazoles and isoindolones.

Abstract translation: 本发明涉及环状取代的稠合吡咯并咔唑和异吲哚酮。 本发明还涉及制备和使用环状取代的稠合吡咯并咔唑和异吲哚酮的方法。

公开(公告)号：US20020055616A1

公开(公告)日：2002-05-09

申请号：US09879336

申请日：2001-06-12

Applicant: Cephalon, Inc.

Inventor： Sankar Chatterjee ,  John P. Mallamo ,  Ron Bihovsky ,  Gregory J. Wells

IPC: C07K005/08 ,  C07K005/10 ,  C07D41/02

CPC classification number: C07D207/08 ,  C07C311/06 ,  C07C311/46 ,  C07C311/48 ,  C07D207/20 ,  C07D207/48 ,  C07D211/76 ,  C07D211/96 ,  C07D213/70 ,  C07D213/74 ,  C07D235/06 ,  C07D239/42 ,  C07D275/06 ,  C07D277/40 ,  C07D277/54 ,  C07D333/34 ,  C07D333/62 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07K5/0202 ,  C07K5/06069

Abstract: This invention relates to peptide-containing null-ketoamide inhibitors of cysteine and serine proteases, methods for making these compounds, and methods for using the same.

Abstract translation: 本发明涉及半胱氨酸和丝氨酸蛋白酶的含肽α-酮酰胺抑制剂，制备这些化合物的方法及其使用方法。

公开(公告)号：US20220185902A1

公开(公告)日：2022-06-16

申请号：US17538530

申请日：2021-11-30

Applicant: Cephalon, Inc.

Inventor： Lynn Dorothy POULTON ,  Matthew Pollard ,  Anthony G. Doyle ,  Bridget A. Cooksey ,  Vanya Pande ,  Adam W. Clarke

IPC: C07K16/28 ,  A61P11/06 ,  C07K16/24

Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.